Navigation Links
Bedford Laboratories(TM) to Begin Shipping Ceftriaxone for Injection USP
Date:7/16/2009

BEDFORD, Ohio, July 16 /PRNewswire/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories, Inc., announced FDA approval to begin shipping Ceftriaxone for Injection USP. This product is AP rated and is equivalent to Rocephin(R) by Roche. Ceftriaxone is a semisynthetic, broad-spectrum antibiotic used to treat several types of infections caused by susceptible bacteria.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO )

"In our continuing effort to offer the most comprehensive and cost effective line of injectables in the multisource industry, Bedford Laboratories is pleased to begin offering this product which represents Bedford's entry into the cephalosporin market. This continues to demonstrate our commitment to providing a broad based portfolio of products," said David Gaugh, Vice President and General Manager of Bedford Laboratories.

Bedford Laboratories will supply Ceftriaxone for Injection USP as a sterile crystalline powder in glass vials in the following presentations: Single-dose vials containing either 250mg, 500mg, 1g, or 2g equivalent of ceftriaxone packaged in cartons containing 10 vials and a pharmacy bulk vial containing the equivalent of 10g ceftriaxone packaged in cartons containing 1 vial.

Prescribing information is available upon request from the Bedford Laboratories' professional services department at 800.521.5169, or from the company's web site, www.bedfordlabs.com.

About Bedford Laboratories

Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim Corporation

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees. Since it was founded in 1885, the independent, family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of $17 billion (11.6 billion euro) while spending one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit http://us.boehringer-ingelheim.com.

Rocephin(R) is a registered trademark of Hoffmann-La Roche, Inc.


'/>"/>
SOURCE Ben Venue Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bedford Laboratories(TM) to Begin Shipping Sumatriptan Succinate Injection
2. Bedford Laboratories(TM) to Begin Shipping Irinotecan HCl Injection
3. Children of New Bedford Immigrant Raids Are Victims of Terrorism, Testifies Dr. Laria Today
4. Bedford Laboratories(TM) Announces the Acquisition of CAFCIT(R) (Caffeine Citrate) Injection CAFCIT(R) (Caffeine Citrate) Oral Solution
5. Promising hematologists begin year-long program to pursue careers in clinical research
6. 2009 recipient of minority scholar award begins clinical research on leukemia
7. Dove and Early Canada Goose Seasons to Begin Sept. 1; Game Commission Posts Avian Influenza Information on Website
8. Online Voting Begins for Ford Customer Service Divisions Second Annual Funny Car Design Contest to Support Juvenile Diabetes Research Foundation
9. Successful Beginning for Wellstone Muscular Dystrophy Center at Boston Biomedical Research Institute
10. Biostar Pharmaceuticals, Inc. Begins Construction of Raw Material Processing Facility of the Herbal Plantation Base
11. Beginning Swim Classes Too Advanced for Many Beginners; Swim Instructor Conference Slated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: